文献速递细菌感染、耐药与抗菌药物艾滋病与性传播感染

男男性行为者生殖支原体感染高流行且耐药率高:ANRS IPERGAY暴露前预防试验子研究

High Prevalence and High Rate of Antibiotic Resistance of Mycoplasma genitalium Infections in Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Pre-exposure Prophylaxis Trial.
PubMed 文献 · Clin Infect Dis · 2021-01-01

该研究在ANRS IPERGAY开放标签阶段纳入210名MSM,基线与6个月时用实时PCR检测尿液、肛拭子和咽拭子中的生殖支原体(MG),并在法国国家细菌性STI参考中心检测阿奇霉素、氟喹诺酮类和多西环素耐药。基线全部位MG流行率为10.5%,6个月时无论是否使用多西环素PEP均未见下降(总体9.9%,PEP组10.2%,无PEP组9.6%);AZM与FQ耐药率分别为67.6%和9.1%,提示该人群MG治疗面临挑战。

要点

  • 基线全部位MG流行率10.5%,尿液6.3%、肛拭子4.3%、咽拭子0.5%。
  • 6个月时MG流行率总体9.9%,PEP组10.2%、无PEP组9.6%,多西环素PEP未降低感染率。
  • AZM耐药率67.6%、FQ耐药率9.1%,支持避免对无症状MG感染进行检测或治疗。

核心结论

  • MSM暴露前预防人群中MG感染流行率高,多西环素PEP未降低其发生率,且AZM与FQ耐药率均高。

研究设计与样本

  • ANRS IPERGAY试验开放标签阶段子研究,210名受试者在基线和6个月时接受尿液、口咽及肛拭子实时PCR检测。
  • 耐药检测在法国国家细菌性STI参考中心进行,评估AZM、FQ和多西环素耐药。

主要发现

  • 基线全部位MG流行率为10.5%,尿液6.3%、肛拭子4.3%、咽拭子0.5%。
  • 6个月时MG流行率总体9.9%,PEP组10.2%、无PEP组9.6%。
  • 总体MG对AZM和FQ耐药率分别为67.6%和9.1%,两组间无差异。
  • 12.5%的受检标本观察到可能与四环素耐药相关的MG 16S rRNA体内突变。

关键数值与推荐

  • 基线全部位MG流行率10.5%(尿液6.3%、肛拭子4.3%、咽拭子0.5%)。
  • 6个月MG流行率总体9.9%,PEP组10.2%、无PEP组9.6%。
  • AZM耐药率67.6%,FQ耐药率9.1%。
  • 12.5%的受检标本存在MG 16S rRNA体内突变。

临床怎么用

  • 该人群MG感染及耐药率高,治疗选择受限,应避免对无症状MG感染进行检测或治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mycoplasma genitalium (MG) is an emerging pathogen among men who have sex with men (MSM) with raising rates of antibiotic resistance. This study assessed the prevalence and incidence of MG infection in MSM enrolled in the open-label phase of the ANRS IPERGAY trial with on-demand tenofovir disoproxil fumarate/emtricitabine for human immunodeficiency virus prevention and the impact of doxycycline post-exposure prophylaxis (PEP). METHODS: 210 subjects were tested at baseline and at 6 months by real-time PCR assays for MG detection in urine samples and oropharyngeal and anal swabs. Resistance to azithromycin (AZM), to fluoroquinolones (FQs), and to doxycycline was investigated in the French National Reference Center of Bacterial Sexually Transmitted Infections (STIs). RESULTS: The all-site prevalence of MG at baseline was 10.5% (6.3% in urine samples, 4.3% in anal swabs, 0.5% in throat swabs) and remained unchanged at 6 months whether or not PEP was used: 9.9% overall, 10.2% with PEP, 9.6% without. The overall rate of MG resistance (prevalent and incident cases) to AZM and FQs was 67.6% and 9.1%, respectively, with no difference between arms. An in vivo mutation of the MG 16S rRNA, which could be associated with tetracycline resistance, was observed in 12.5% of specimens tested. CONCLUSIONS: The prevalence of MG infection among MSM on pre-exposure prophylaxis was high and its incidence was not decreased by doxycycline prophylaxis with a similar high rate of AZM and FQ resistance, raising challenging issues for the treatment of this STI and supporting current recommendations to avoid testing or treatment of asymptomatic MG infection.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Berçot B, Charreau I, Rousseau C, et al. High Prevalence and High Rate of Antibiotic Resistance of Mycoplasma genitalium Infections in Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Pre-exposure Prophylaxis Trial. Clin Infect Dis. 2021. PMID: 33305785. doi:10.1093/cid/ciaa1832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。